Combinatorial treatment with traditional medicinal preparations and VEGFR-tyrosine kinase inhibitors for middle-advanced primary liver cancer: A systematic review and meta-analysis

Hui-Bo Yu, Jia-Qi Hu, Bao-Jin Han, Yan-Yuan Du, Shun-Tai Chen, Xin Chen, Hong-Tai Xiong, Jin Gao and Hong-Gang Zheng

PLOS ONE, 2024, vol. 19, issue 11, 1-32

Abstract: Background: This study aimed to investigate the therapeutic efficacy and safety of Traditional medicine preparations (TMPs) given in combination with vascular endothelial growth factor receptor (VEGFR)-associated multi-targeted tyrosine kinase inhibitors (TKIs) for the treatment of middle to advanced-stage primary liver cancer (PLC). Methods: This systematic literature survey employed 10 electronic databases and 2 clinical trial registration platforms to identify relevant studies on the use of TMPs + VEGFR-TKIs to treat patients with middle-advanced PLC. Furthermore, a meta-analysis was performed following the PRISMA guidelines using the risk ratio (RR) at 95% confidence intervals (CI) or standardized mean difference as effect measures. Results: A total of 26 studies comprising 1678 middle-advanced PLC patients were selected. The meta-analysis revealed that compared with VEGFR-TKI mono-treatment, the co-therapy of TMPs + VEGFR-TKIs considerably enhanced the objective response rate (RR = 1.49, 95% CI: 1.31–1.69), disease control rate (RR = 1.23, 95% CI: 1.16–1.30), and one-year overall survival (RR = 1.49, 95% CI: 1.28–1.74). Furthermore, the co-therapy was associated with reduced incidences of liver dysfunction (RR = 0.64, 95% CI: 0.45–0.91), proteinuria (RR = 0.43, 95% CI: 0.24–0.75), hypertension (RR = 0.66, 95% CI: 0.53–0.83), hand-foot skin reactions (RR = 0.63, 95% CI: 0.49–0.80), myelosuppression (RR = 0.63, 95% CI: 0.46–0.87), and gastrointestinal reactions (RR = 0.64, 95% CI: 0.45–0.92). Moreover, the co-therapy indicated no increase in the incidences of rash and fatigue. Conclusion: This systematic analysis revealed that co-therapy with TMPs + VEGFR-TKIs has a higher effectiveness and safety profile for treating middle-advanced PLC patients. However, further validation using randomized control trials is required. PROSPERO registration no: CRD42022350634.

Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0313443 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 13443&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0313443

DOI: 10.1371/journal.pone.0313443

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().